
Please try another search
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of LTX-315 for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma AS was founded in 2003 and is based in Oslo, Norway.
Name | Age | Since | Title |
---|---|---|---|
James Patrick Allison | - | 2019 | Member of Scientific Advisory Board |
Padmanee Sharma | - | 2019 | Member of Scientific Advisory Board |
Aurelien Marabelle | - | - | Member of Scientific Advisory Board |
Robert H.I. Andtbacka | - | - | Member of Advisory Board |
Brynjar Kristian Forbergskog | 67 | 2021 | Non-Executive Independent Director |
Kjetil Hestdal | 65 | 2021 | Non-Executive Independent Director |
Marie-Louise Helena Fjallskog | 61 | 2021 | Independent Director |
Claus Asbjorn Andersson | 57 | 2025 | Director |
Eric Falcand | 62 | 2025 | Chair of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review